A combined biomarker pattern improves the discrimination of lung cancer.

A total of 227 sera were analysed using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) to find novel serum biomarkers for lung cancer. The results showed that the 11.53, 11.

[A new serum biomarker for lung cancer - transthyretin.].

Background: Lung cancer is the leading cause of cancer death worldwide and very few specific biomarkers could be used in clinical diagnosis at present. The aim of this study is to find novel potential serum biomarkers for lung cancer using Surface Enhanced Laser Desorption/Ionization (SELDI) technique.

Methods: Serum sample of 227 cases including 146 lung cancer, 13 pneumonia, 28 tuberculous pleurisy and 40 normal individuals were analyzed by CM10 chips.

Serum levels of variants of transthyretin down-regulation in cholangiocarcinoma.

Background: Cholangiocarcinoma (CC) is devastating neoplasm and very few specific biomarkers could be used in clinical diagnosis. A study was taken to find novel serum biomarkers for CC.

Methods: Surface enhanced laser desorption/ionization (SELDI) technology was used to analyze 427 serum samples including 56 CCs, 49 hepatobiliary diseases, 269 other cancer control, and 53 healthy individuals.

Reduced transthyretin expression in sera of lung cancer.

Lung cancer is a leading cause of cancer death worldwide, and very few specific biomarkers can be used in its clinical diagnosis. Using surface-enhanced laser desorption-ionization time-of-flight mass spectrometry (MS) to find novel serum biomarkers for lung cancer, we analyzed 227 serum samples, including 146 lung cancers, 41 benign lung diseases and 40 normal individuals. Three peaks, at 13.

Discovery and identification of Serum Amyloid A protein elevated in lung cancer serum.

Two hundred and eighteen serum samples from 175 lung cancer patients and 43 healthy individuals were analyzed by using Surface Enhaced Laser Desorption/Ionization Time of Flight Mass Spectrome-try (SELDI-TOF-MS). The data analyzed by both Biomarker Wizardtrade mark and Biomarker Patternstrade mark software showed that a protein peak with the molecular weight of 11.6 kDa significantly increased in lung cancer.

Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer.

Objective: To identify serum diagnosis or progression biomarkers in patients with lung cancer using protein chip profiling analysis.

Method: Profiling analysis was performed on 450 sera collected from 213 patients with lung cancer, 19 with pneumonia, 16 with pulmonary tuberculosis, 65 with laryngeal carcinoma, 55 with laryngopharyngeal carcinoma patients, and 82 normal individuals. A new strategy was developed to identify the biomarkers on chip by trypsin pre-digestion.